[Comparison of the variations in the levels of beta2-microglobulin and carcino-embryonic antigen in the breast cancer and malignant melanoma (author's transl)].
A variety of markers have been used in the surveillance of carcinoma of the breast and malignant melanoma, including carcino-embryonic antigen (CEA) beta2-microglobulin (beta2m) and prolactin. The dual purpose of the surveillance was the detection of early recurrence or metastasis and the monitoring of the treatment. In cancer of the breast 92% of patients having bone metastases have elevated levels of CEA or beta2m. In malignant melanoma 2/3 of the patients in relapse have elevated beta2m levels.
D001609:Beta-Globulins / Q000032:analysis*; D001859:Bone Neoplasms / Q000097:blood / Q000276:immunology; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D005500:Follow-Up Studies; D006801:Humans; D008545:Melanoma / Q000097:blood / Q000276:immunology*; D009362:Neoplasm Metastasis; D011388:Prolactin / Q000097:blood; D001613:beta 2-Microglobulin / Q000032:analysis*
D001609:Beta-Globulins; D002272:Carcinoembryonic Antigen; D001613:beta 2-Microglobulin; D011388:Prolactin
Comparaison de l'évolution des taux de la beta2-microglobuline et de l'antigène carcino-embryonnaire dans les cancers du sein et les mélanomes malins.